New drug aims to help dialysis patients manage dangerous mineral levels
NCT ID NCT07285304
First seen Dec 16, 2025 · Last updated Apr 17, 2026 · Updated 19 times
Summary
This study is testing the long-term safety and effectiveness of an investigational drug called TS-172. It is for adults on kidney dialysis who have high levels of phosphate in their blood, a common and serious problem. The goal is to see if TS-172 can safely help control these phosphate levels over time when used alongside standard phosphate binder medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.